CLINICAL_TRIALS trial_result · 2022-10-26

Clinical Trial Update: A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD [Phase 2]

Phase 2 trial evaluating AKST4290 in combination with aflibercept for neovascular age-related macular degeneration has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Alkahest, Inc. | Conditions: Neovascular Age-related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2022-10-26